Home » FDA Warns That Tecentriq and Paclitaxel Combination Doesn’t Work for Breast Cancer
FDA Warns That Tecentriq and Paclitaxel Combination Doesn’t Work for Breast Cancer
September 10, 2020
The FDA warned that Roche’s Tecentriq (atezolizumab) and paclitaxel did not work as a treatment for previously untreated inoperable locally advanced or metastatic triple-negative breast cancer (mTNBC).
In a phase 3 trial, the combination did not significantly reduce the risk of cancer progression and death compared with a placebo and paclitaxel in mTNBC patients whose tumors express the PD-LI protein.
Tecentriq is currently approved with a different form of paclitaxel, Abraxane (paclitaxel protein-bound), for adults with mTNBC whose tumors express the PD-L1 protein. The FDA advised healthcare providers not to use paclitaxel in place of Abraxane (paclitaxel protein-bound).
Upcoming Events
-
21Oct